By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

This was the stock's second consecutive day of gains.

Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...

The stock's fall snapped a two-day winning streak.

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type ...

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.